Tetrameric Transthyretin as a Protective Factor Against Alzheimer's Disease.
Alzheimer’s disease
Amyloidosis
Neuroprotection
Therapeutic strategies
Transthyretin
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
received:
22
05
2024
accepted:
13
08
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Transthyretin (TTR) is a tetrameric protein traditionally recognized for its role in transporting thyroxine and retinol. Recent research has highlighted the potential neuroprotective functions of TTR in the setting of Alzheimer's disease (AD), which is the most common form of dementia and is caused by the deposition of amyloid beta (Aβ) and the resulting cytotoxic effects. This paper explores the mechanisms of TTR protective action, including its interaction with Aβ to prevent fibril formation and promote Aβ clearance from the brain. It also synthesizes experimental evidence suggesting that enhanced TTR stability may mitigate neurodegeneration and cognitive decline in AD. Potential therapeutic strategies such as small molecule stabilizers of TTR are discussed, highlighting their role in enhancing TTR binding to Aβ and facilitating its clearance. By consolidating current knowledge and proposing directions for future research, this review aims to underscore the significance of TTR as a neuroprotective factor in AD and the potential implications for future research.
Identifiants
pubmed: 39192044
doi: 10.1007/s12035-024-04442-8
pii: 10.1007/s12035-024-04442-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization, Dementia, 2023. https://www.who.int/en/news-room/fact-sheets/detail/dementia (last access May 10, 2024).
Alzheimer's Disease International, Dementia Statistics. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ (last access May 10, 2024).
World Health Organization, The top 10 causes of death, 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (last access May 10, 2024).
McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944
pubmed: 6610841
doi: 10.1212/WNL.34.7.939
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzh Dem 7:263–269
Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804
pubmed: 22784036
pmcid: 3474597
doi: 10.1056/NEJMoa1202753
RijalUpadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamaguchi H, Fändrich M et al (2014) Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease. Brain 137:887–903
doi: 10.1093/brain/awt362
Gauthreaux K, Bonnett TA, Besser LM et al (2020) Concordance of clinical Alzheimer diagnosis and neuropathological features at autopsy. J Neuropathol Experiment Neurol 79:465–473
doi: 10.1093/jnen/nlaa014
Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA Research framework: toward a biological definition of Alzheimer’s disease. Alzh Dem 14:535–562
Kantarci K (2014) Molecular imaging of Alzheimer disease pathology. Am J Neuroradiol 35:S12–S17
pubmed: 24503555
doi: 10.3174/ajnr.A3847
Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128:1554–1575
pubmed: 33983835
pmcid: 8561842
doi: 10.1161/CIRCRESAHA.121.318187
Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer’s disease. Lancet 397:1577–1590
pubmed: 33667416
pmcid: 8354300
doi: 10.1016/S0140-6736(20)32205-4
Gião T, Saavedra J, Cotrina E et al (2020) Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer’s disease. Int J Mol Sci 21:2075
pubmed: 32197355
pmcid: 7139926
doi: 10.3390/ijms21062075
Buxbaum JN (2023) The role of CSF transthyretin in human Alzheimer’s disease: offense, defense, or not so innocent bystander. J Integr Neurosci 22:158
pubmed: 38176942
doi: 10.31083/j.jin2206158
Blake CC, Swan ID, Rerat C et al (1971) An x-ray study of the subunit structure of prealbumin. J Mol Biol 61:217–224
pubmed: 5146194
doi: 10.1016/0022-2836(71)90218-X
Sparkes RS, Sasaki H, Mohandas T et al (1987) Assignment of the prealbumin (PALB) gene (familial amyloidotic polyneuropathy) to human chromosome region 18q11.2–q12.1. Hum Gen 75:151–4
doi: 10.1007/BF00591077
Ferguson RN, Edelhoch H, Saroff HA, Robbins J, Cahnmann HJ (1975) Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid. Biochemistry 14:282–9
pubmed: 1120103
doi: 10.1021/bi00673a014
Johnson SM, Wiseman RL, Sekijima Y et al (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38:911–921
pubmed: 16359163
doi: 10.1021/ar020073i
Monaco HL, Rizzi M, Coda A (1995) Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268:1039–1041
pubmed: 7754382
doi: 10.1126/science.7754382
Malpeli G, Folli C, Berni R (1996) Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin. Biochim Biophys Acta 1294:48–54
pubmed: 8639713
doi: 10.1016/0167-4838(95)00264-2
Wieczorek E, Ożyhar A (2021) Transthyretin: from structural stability to osteoarticular and cardiovascular diseases. Cells 10(7):1768. https://doi.org/10.3390/cells10071768
Si JB, Kim B, Kim JH (2021) Transthyretin misfolding, a fatal structural pathogenesis mechanism. Int J Mol Sci. 22(9):4429. https://doi.org/10.3390/ijms22094429
Sanguinetti C, Minniti M, Susini V et al (2022) The journey of human transthyretin: synthesis, structure stability, and catabolism. Biomedicines 10(8):1906
Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS (1985) Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 260:11793–11798
pubmed: 4044580
doi: 10.1016/S0021-9258(17)39100-7
Wang Z, Burke PA (2010) Hepatocyte nuclear factor-4α interacts with other hepatocyte nuclear factors in regulating transthyretin gene expression. FEBS J 277:4066–4075
pubmed: 20735474
pmcid: 2939928
doi: 10.1111/j.1742-4658.2010.07802.x
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8:1390–1397
pubmed: 12415260
doi: 10.1038/nm1202-793
Landers KA, Mortimer RH, Richard K (2013) Transthyretin and the human placenta. Placenta 34:513–517
pubmed: 23664144
doi: 10.1016/j.placenta.2013.04.013
Soprano DR, Soprano KJ, Goodman DS (1986) Retinol-binding protein and transthyretin mRNA levels in visceral yolk sac and liver during fetal development in the rat. Proc Natl Acad Sci USA 83:7330–7334
pubmed: 3463972
pmcid: 386710
doi: 10.1073/pnas.83.19.7330
Su Y, Jono H, Misumi Y, Senokuchi T, Guo J, Ueda M et al (2012) Novel function of transthyretin in pancreatic alpha cells. FEBS Lett 586:4215–4222
pubmed: 23108050
doi: 10.1016/j.febslet.2012.10.025
Refai E, Dekki N, Yang SN et al (2005) Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling. Proc Nat Acad Sci USA 102:17020–17025
pubmed: 16286652
pmcid: 1287967
doi: 10.1073/pnas.0503219102
Cavallaro T, Martone RL, Dwork AJ, Schon EA, Herbert J (1990) The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophtalm Vis Sci 31:497–501
Pfeffer BA, Becerra SP, Borst DE, Wong P (2004) Expression of transthyretin and retinol binding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. Mol Vis 10:23–30
pubmed: 14737066
Lee CC, Ding X, Zhao T et al (2019) Transthyretin stimulates tumor growth through regulation of tumor, immune, and endothelial cells. J Immunol 202:991–1002
pubmed: 30567728
doi: 10.4049/jimmunol.1800736
Lee EJ, Bhat AR, Kamli MR et al (2013) Transthyretin is a key regulator of myoblast differentiation. PLoS ONE 8:e63627
pubmed: 23717457
pmcid: 3661549
doi: 10.1371/journal.pone.0063627
Murakami T, Sango K, Watabe K et al (2015) Schwann cells contribute to neurodegeneration in transthyretin amyloidosis. J Neurochem 134:66–74
pubmed: 25693163
doi: 10.1111/jnc.13068
Li X, Masliah E, Reixach N, Buxbaum JN (2011) Neuronal production of transthyretin in human and murine Alzheimer’s disease: is it protective? J Neurosci 31:12483–12490
pubmed: 21880910
pmcid: 3172869
doi: 10.1523/JNEUROSCI.2417-11.2011
Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22:7380–7388
pubmed: 12196559
pmcid: 6758007
doi: 10.1523/JNEUROSCI.22-17-07380.2002
Silva CS, Eira J, Ribeiro CA et al (2017) Transthyretin neuroprotection in Alzheimer’s disease is dependent on proteolysis. Neurobiol Aging 59:10–14
pubmed: 28780366
doi: 10.1016/j.neurobiolaging.2017.07.002
Makover A, Moriwaki H, Ramakrishnan R et al (1988) Plasma transthyretin. Tissue sites of degradation and turnover in the rat. J Biol Chem 263:8598–603
pubmed: 3379035
doi: 10.1016/S0021-9258(18)68346-2
Sousa MM, Saraiva MJ (2001) Internalization of transthyretin. Evidence of a novel yet unidentified receptor-associated protein (RAP)-sensitive receptor. J Biol Chem 276:14420–5
pubmed: 11278770
doi: 10.1074/jbc.M010869200
Palha JA (2002) Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med 40:1292–1300
pubmed: 12553433
doi: 10.1515/CCLM.2002.223
Raz A, Goodman DS (1969) The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 244:3230–3237
pubmed: 4978316
doi: 10.1016/S0021-9258(18)93118-2
Episkopou V, Maeda S, Nishiguchi S et al (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Nat Acad Sci USA 90:2375–2379
pubmed: 8384721
pmcid: 46089
doi: 10.1073/pnas.90.6.2375
Monk JA, Sims NA, Dziegielewska KM et al (2013) Delayed development of specific thyroid hormone-regulated events in transthyretin null mice. Am J Physiol Endocrinol Metab 304:E23-31
pubmed: 23092911
doi: 10.1152/ajpendo.00216.2012
Liz MA, Gomes CM, Saraiva MJ, Sousa MM (2007) ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lip Res 48:2385–2395
doi: 10.1194/jlr.M700158-JLR200
Liz MA, Fleming CE, Nunes AF et al (2009) Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochem J 419:467–474
pubmed: 19138167
doi: 10.1042/BJ20082090
Pain S, Brot S, Gaillard A (2022) Neuroprotective effects of neuropeptide Y against neurodegenerative disease. Curr Neuropharmacol 20:1717–1725
pubmed: 34488599
pmcid: 9881060
doi: 10.2174/1570159X19666210906120302
Fleming CE, Saraiva MJ, Sousa MM (2007) Transthyretin enhances nerve regeneration. J Neurochem 103:831–839
pubmed: 17897357
doi: 10.1111/j.1471-4159.2007.04828.x
Fleming CE, Mar FM, Franquinho F, Saraiva MJ, Sousa MM (2009) Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci 29:3220–3232
pubmed: 19279259
pmcid: 6666452
doi: 10.1523/JNEUROSCI.6012-08.2009
Gomes JR, Nogueira RS, Vieira M et al (2016) Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ 23(11):1749–1764. https://doi.org/10.1038/cdd.2016.64
doi: 10.1038/cdd.2016.64
pubmed: 27518433
pmcid: 5071567
Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA (2007) Transthyretin influences spatial reference memory. Neurobiol Learn Mem 88(3):381–385
pubmed: 17698379
doi: 10.1016/j.nlm.2007.07.006
Brouillette J, Quirion R (2008) Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 29:1721–1732
pubmed: 17512093
doi: 10.1016/j.neurobiolaging.2007.04.007
Magalhães J, Eira J, Liz MA (2021) The role of transthyretin in cell biology: impact on human pathophysiology. Cell Mol Life Sci 78:6105–6117
pubmed: 34297165
pmcid: 11073172
doi: 10.1007/s00018-021-03899-3
Vancamp P, Gothié JD, Luongo C et al (2019) Gender-specific effects of transthyretin on neural stem cell fate in the subventricular zone of the adult mouse. Sci Rep 9:19689
pubmed: 31873158
pmcid: 6927974
doi: 10.1038/s41598-019-56156-w
Ishii A, Furusho M, Dupree JL, Bansal R (2016) Strength of ERK1/2 MAPK activation determines its effect on myelin and axonal integrity in the adult CNS. J Neurosci 36:6471–6487
pubmed: 27307235
pmcid: 5015783
doi: 10.1523/JNEUROSCI.0299-16.2016
Vieira M, Gomes JR, Saraiva MJ (2015) Transthyretin induces insulin-like growth factor i nuclear translocation regulating its levels in the hippocampus. Mol Neurobiol 51:1468–1479
pubmed: 25084758
doi: 10.1007/s12035-014-8824-4
Thal DR, Gawor K (2023) Cerebral amyloid angiopathy: neuropathological diagnosis, link to Alzheimer’s disease and impact on clinics. Clin Neuropathol 42:176–189
pubmed: 37489069
doi: 10.5414/NP301564
Taipa R, Sousa L, Pinto M et al (2023) Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathol 145:113–126
pubmed: 36198883
doi: 10.1007/s00401-022-02501-9
Maia LF, Magalhães R, Freitas J et al (2015) CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Phsych 86:159–167
doi: 10.1136/jnnp-2014-308107
Durmuş H, Çakar A, Demirci H et al (2021) An exploratory study of cognitive involvement in hereditary transthyretin amyloidosis. Acta Neurol Scand 144:640–646
pubmed: 34322872
doi: 10.1111/ane.13507
Martins da Silva A, Cavaco S, Fernandes J et al (2018) Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol 265:299–307
pubmed: 29209781
doi: 10.1007/s00415-017-8668-8
Hamasaki H, Shijo M, Nakamura A et al (2022) Concurrent cardiac transthyretin and brain β amyloid accumulation among the older adults: the Hisayama study. Brain Pathol 32:e13014
pubmed: 34390072
doi: 10.1111/bpa.13014
Sanna GD, Nusdeo G, Piras MR et al (2019) Cardiac abnormalities in Alzheimer disease: clinical relevance beyond pathophysiological rationale and instrumental findings? JACC Heart Fail 7:121–128
pubmed: 30704603
doi: 10.1016/j.jchf.2018.10.022
Troncone L, Luciani M, Coggins M et al (2016) Aβ amyloid pathology affects the hearts of patients with Alzheimer’s disease: mind the heart. J Am Coll Cardiol 68:2395–2407
pubmed: 27908343
pmcid: 5142757
doi: 10.1016/j.jacc.2016.08.073
Mawuenyega KG, Sigurdson W, Ovod V et al (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330:1774
pubmed: 21148344
pmcid: 3073454
doi: 10.1126/science.1197623
Sheppard O, Coleman M (2020) Alzheimer’s disease: etiology, neuropathology and pathogenesis. In: Huang X (ed) Chapter 1: Alzheimer’s disease: drug discovery. Exon Publications, Brisbane. Available from: https://www.ncbi.nlm.nih.gov/books/NBK566126/ https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch1
Lewis J, Dickson DW, Lin WL et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491
pubmed: 11520987
doi: 10.1126/science.1058189
Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491–1495
pubmed: 11520988
doi: 10.1126/science.1062097
Ma C, Hong F, Yang S. (2022) Amyloidosis in Alzheimer's disease: pathogeny, etiology, and related therapeutic directions. Molecules 27
Tarasoff-Conway JM, Carare RO, Osorio RS et al (2015) Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11:457–470
pubmed: 26195256
pmcid: 4694579
doi: 10.1038/nrneurol.2015.119
Wisniewski T, Castano E, Ghiso J, Frangione B (1993) Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. Ann Neurol 34:631–633
pubmed: 8215255
doi: 10.1002/ana.410340422
Schwarzman AL, Gregori L, Vitek MP et al (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Nat Acad Sci USA 91:8368–8372
pubmed: 8078889
pmcid: 44607
doi: 10.1073/pnas.91.18.8368
Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489–1499
pubmed: 11120756
pmcid: 387254
doi: 10.1172/JCI10498
Alemi M, Gaiteiro C, Ribeiro CA et al (2016) Transthyretin participates in beta-amyloid transport from the brain to the liver–involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep 6:20164
pubmed: 26837706
pmcid: 4738280
doi: 10.1038/srep20164
Costa R, Gonçalves A, Saraiva MJ, Cardoso I (2008) Transthyretin binding to A-Beta peptide–impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582:936–942
pubmed: 18295603
doi: 10.1016/j.febslet.2008.02.034
Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV (2018) Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Prot Sci 27:1252–1261
doi: 10.1002/pro.3396
Du J, Murphy RM (2010) Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers. Biochemistry 49:8276–8289
pubmed: 20795734
doi: 10.1021/bi101280t
Sekijima Y, Tokuda T, Kametani F et al (2001) Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid 8:257–262
pubmed: 11791618
doi: 10.3109/13506120108993822
Du J, Cho PY, Yang DT, Murphy RM (2012) Identification of beta-amyloid-binding sites on transthyretin. Prot Engin Des Sel 25:337–345
doi: 10.1093/protein/gzs026
Li X, Zhang X, Ladiwala AR et al (2013) Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci 33:19423–19433
pubmed: 24336709
pmcid: 3858619
doi: 10.1523/JNEUROSCI.2561-13.2013
Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS ONE 3:e2899
pubmed: 18682830
pmcid: 2483353
doi: 10.1371/journal.pone.0002899
Li X, Song Y, Sanders CR, Buxbaum JN (2016) Transthyretin suppresses amyloid-β secretion by interfering with processing of the amyloid-β protein precursor. J Alzh Dis 52:1263–1275
doi: 10.3233/JAD-160033
Schwarzman AL, Tsiper M, Wente H et al (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11:1–9
pubmed: 15185492
doi: 10.1080/13506120410001667458
Alemi M, Gaiteiro C, Ribeiro CA et al (2016) Transthyretin participates in beta-amyloid transport from the brain to the liver–involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep 6:20164
pubmed: 26837706
pmcid: 4738280
doi: 10.1038/srep20164
Ribeiro CA, Santana I, Oliveira C et al (2012) Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. Curr Alzheimer Res 9:881–889
pubmed: 22698061
doi: 10.2174/156720512803251057
Wang Y, Liu W, Sun Y, Dong X (2024) Transthyretin-penetratin: a potent fusion protein inhibitor against Alzheimer’s amyloid-β fibrillogenesis with high blood brain barrier crossing capability. Bioconjug Chem 35:419–431
pubmed: 38450606
doi: 10.1021/acs.bioconjchem.4c00073
Cotrina EY, Gimeno A, Llop J et al (2020) Calorimetric studies of binary and ternary molecular interactions between transthyretin, aβ peptides, and small-molecule chaperones toward an alternative strategy for alzheimer’s disease drug discovery. J Med Chem 63:3205–3214
pubmed: 32124607
pmcid: 7115756
doi: 10.1021/acs.jmedchem.9b01970
Ribeiro CA, Saraiva MJ, Cardoso I (2012) Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide–relevance in Alzheimer’s disease. PLoS ONE 7:e45368
pubmed: 23028965
pmcid: 3444465
doi: 10.1371/journal.pone.0045368
Ribeiro CA, Oliveira SM, Guido LF et al (2014) Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer’s disease mouse model. J Alzh Dis 39:357–370
doi: 10.3233/JAD-131355
Coelho T, Maia LF, Martins da Silva A et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785–92
pubmed: 22843282
pmcid: 4098875
doi: 10.1212/WNL.0b013e3182661eb1